Additive IOP‐reducing effect of latanoprost in patients insufficiently controlled on timolol

Purpose: To evaluate the effect on intraocular pressure (IOP) of switching from timolol to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol. Methods: This was a 6‐week, double‐masked, randomis...

Full description

Saved in:
Bibliographic Details
Published in:Acta ophthalmologica Scandinavica 2001-06, Vol.79 (3), p.289-293
Main Authors: Bron, Alain M., Denis, Philippe, Nordmann, Jean‐Philippe, Rouland, Jean‐François, Sellem, Eric, Johansson, Marianne
Format: Article
Language:English
Subjects:
additivity
Adult
Aged
Aged, 80 and over
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Double-Blind Method
Drug Synergism
Drug Therapy, Combination
Female
Glaucoma, Open-Angle - drug therapy
Humans
Intraocular Pressure - drug effects
latanoprost
Life Sciences
Male
Middle Aged
Ocular Hypertension - drug therapy
open angle glaucoma
Ophthalmic Solutions
Prostaglandins F, Synthetic - adverse effects
Prostaglandins F, Synthetic - therapeutic use
switch
timolol
Timolol - adverse effects
Timolol - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: To evaluate the effect on intraocular pressure (IOP) of switching from timolol to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol. Methods: This was a 6‐week, double‐masked, randomised multi‐centre study. 53 patients with primary open angle glaucoma, capsular glaucoma, or ocular hypertension with an IOP of at least 21 mmHg on current therapy were recruited. After a run‐in period of at least 2 weeks on timolol, 5 mg/ml twice daily, patients were randomised to one of three groups. One group continued on timolol, one switched from timolol to latanoprost, 50 μg/ml once daily, and a third group received latanoprost in addition to timolol. The efficacy was evaluated by comparing IOP at 9 AM at baseline and after 6 weeks of treatment. Results: IOP at baseline and after 6 weeks of treatment (mean±SEM) were 24.2±0.9 and 23.8±1.0 mmHg (n=16) for patients continuing on timolol, 26.3±1.2 and 19.6±1.1 mmHg (n=17) for patients switching to latanoprost, and 23.2±1.0 and 17.5±0.8 mmHg (n=17) for patients with combined treatment. Adding latanoprost to timolol reduced IOP with 5.9±0.9 mmHg (p
ISSN:1395-3907
1600-0420
DOI:10.1034/j.1600-0420.2001.790316.x